endometrial hyperplasia/offita

Krækjan er vistuð á klemmuspjaldið

Veldu tegund tegund

Bls 1 frá 175 niðurstöður

Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

This is a preliminary study investigating the efficacy of aromatase inhibitor anastrozole in treating endometrial hyperplasia in obese postmenopausal women. We administered anastrozole for 12 months to 11 obese postmenopausal women with high operative risk, in order to treat endometrial hyperplasia

[Incidence of the risk factors age and obesity in patients with endometrial hyperplasia].

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

This investigation pursued the question of how many patients with precancerous endometrial hyperplasia were not recommended for screening programs solely because of the lack of risk factors. The median age of precancerous hyperplasia patients in Erlangen is 54, 8 years before the median age for

Endometrial polyps associated with endometrial hyperplasia in an obese bonnet monkey (Macaca radiata): a case report.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

BACKGROUND A 10-year-old, female bonnet monkey (Macaca radiata) showed abnormal menstrual cycle length with heavy menstrual bleeding for 6-8 days. METHODS Uterine ultrasound and histological examinations of endometrium by endometrial biopsy. RESULTS An ultrasound examination of the uterine cavity

Serum adiponectin in relation to endometrial cancer and endometrial hyperplasia with atypia in obese women.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

OBJECTIVE The aim of this work was to compare concentrations of adiponectin in the serum of obese women with endometrial cancer, endometrial hyperplasia with atypia, and normal endometrium. METHODS We enrolled 105 obese women treated at the Department of Gynecological Surgery and Oncology of Adults

The use of novel technology-based weight loss interventions for obese women with endometrial hyperplasia and cancer.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

OBJECTIVE Obesity significantly increases the risk of the development of both endometrial hyperplasia and cancer. Our objective was to assess the feasibility of two technology-based weight loss interventions in this patient population. METHODS Women with obesity (BMI≥30kg/m(2)) and endometrial

Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

The aim of this retrospective study was to evaluate the efficacy of levonorgestrel intrauterine system-releasing (LNG-IUS) insertion in preventing atypical endometrial hyperplasia (AH) and endometrial cancer (EC) in symptomatic postmenopausal overweight/obese women. A total of 34 overweight/obese

Adipose-derived VEGF-mTOR Signaling Promotes Endometrial Hyperplasia and Cancer: Implications for Obese Women.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Obesity is responsible for increased morbidity and mortality in endometrial cancer. Despite the positive correlation of body mass index (BMI) or obesity in endometrial carcinogenesis, the contribution of adipose tissue to the pathogenesis of endometrial hyperplasia and cancer is unclear. This study

Obesity and endometrial hyperplasia and cancer in premenopausal women: A systematic review.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

To systematically review the literature on the association between obesity and endometrial hyperplasia or cancer in premenopausal women. We searched the bibliographic databases MEDLINE, EMBASE, PubMed, and CINAHL (inception to May 5, 2015), and checked reference lists of included studies and

Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

•Endometrial hyperplasia/carcinoma regression rates with LNG-IUS were examined by BMI.•Morbidly obese patients with EH/EHA/EC are more likely to progress.•Despite addition of oral progesterone to LNG-IUS, morbid obesity increases the odds of progression.

Endometrial hyperplasia, endometrial cancer, and obesity: convergent mechanisms regulating energy homeostasis and cellular proliferation.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Management of abnormal uterine hemorrhage with atypical endometrial hyperplasia by transcervical resection of endometrium.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

The aim of the study was to assess the feasibility and effect of treating atypical endometrial hyperplasia (AEH) with transcervical resection of endometrium (TCRE). Five cases of AEH incapable of hysterectomy for various reasons were treated with TCRE. All patients were followed up for 3-4 years

Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Endometrial hyperplasia is thought to be caused by the prolonged, unopposed oestrogenic stimulation of the endometrium. The regression of hyperplastic back to normal endometrium is the main purpose of any conservative treatment in order to prevent development of adenocarcinoma. The aim of this study

Descriptive epidemiology of endometrial hyperplasia in patients with abnormal uterine bleeding.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

OBJECTIVE To evaluate the prevalence and epidemiologic characteristics of endometrial hyperplasias in women with abnormal uterine bleeding. METHODS We performed a retrospective analysis on data gained from 294 patients with histologically documented endometrial hyperplasia (with or without atypia),

Atypical Endometrial Hyperplasia Arising in a Cesarean Section Scar: A Mechanism of Malignant Transformation.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

The incidence of scar endometriosis in Cesarean sections varies between 0.03 and 0.4%. However, the recently increased rate of Cesarean sections worldwide may be causing an increase in occurrence of scar endometriosis. This report presents anatomopathological evidence of an early-stage malignant

Risk factors for endometrial hyperplasia concomitant endometrial polyps in pre- and post-menopausal women.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

OBJECTIVE To evaluate the risk factors for endometrial hyperplasia concomitant endometrial polyps in pre- and post-menopausal women. METHODS A total of 203 patients undergoing endometrial sampling before hysterectomy were evaluated in this retrospective study. Data recorded were age, gravidity,

Fyrri
1
2
3
4
5
6
...
11
12
Næst

Skráðu þig á
facebook síðu okkar

Herbal & Natural Medicine

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum

Virkar á 55 tungumálum
Jurtalækningar studdir af vísindum
Jurtaviðurkenning eftir ímynd
Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
Lestu vísindarit sem tengjast leit þinni
Leitaðu að lækningajurtum eftir áhrifum þeirra
Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum

Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum